Detailed Information on Publication Record
2023
HPV and RAD51 as Prognostic Factors for Survival in Inoperable Oral and Oropharyngeal Cancer in Patients Unfit for Chemotherapy Treated with Hyperfractionated Radiotherapy
ZDEBLOVA CERMAKOVA, Zuzana, Pavel HURNÍK, David KONVALINKA, Jan STEMBIREK, Tereza PARACKOVA et. al.Basic information
Original name
HPV and RAD51 as Prognostic Factors for Survival in Inoperable Oral and Oropharyngeal Cancer in Patients Unfit for Chemotherapy Treated with Hyperfractionated Radiotherapy
Authors
ZDEBLOVA CERMAKOVA, Zuzana (203 Czech Republic), Pavel HURNÍK (203 Czech Republic, guarantor, belonging to the institution), David KONVALINKA (203 Czech Republic), Jan STEMBIREK (203 Czech Republic), Tereza PARACKOVA, Kamila RESOVA (203 Czech Republic), Jakub CVEK (203 Czech Republic), Tomas BLAZEK (203 Czech Republic), Lukas KNYBEL (203 Czech Republic), Martin FORMANEK (203 Czech Republic), Mariam GACHECHILADZE, Markus JOERGER, Alex SOLTERMANN, Jozef SKARDA, Oldrich MOTYKA (203 Czech Republic) and Jana JANOUTOVA (203 Czech Republic)
Edition
Medicina-Lithuania, Basel, MDPI, 2023, 1010-660X
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30204 Oncology
Country of publisher
Switzerland
Confidentiality degree
není předmětem státního či obchodního tajemství
References:
Impact factor
Impact factor: 2.600 in 2022
RIV identification code
RIV/00216224:14110/23:00130670
Organization unit
Faculty of Medicine
UT WoS
000939961000001
Keywords in English
oropharyngeal cancer; oral cavity cancer; HPV; RAD51; radiotherapy
Změněno: 8/3/2024 12:21, Mgr. Tereza Miškechová
Abstract
V originále
Introduction: The incidence of advanced oral cavity and oropharyngeal cancers is generally high. Treatment outcomes for patients, especially those unfit for comprehensive cancer treatment, are unsatisfactory. Therefore, the search for factors to predict response to treatment and increase overall survival is underway. Objective: This study aimed to analyze the presence of 32 HPV genotypes in tumor samples of 34 patients and the effect of HPV status and RAD51 on overall survival. Method: Tumor samples of 34 patients with locally advanced oropharyngeal or oral cavity cancer treated with accelerated radiotherapy in monotherapy were analyzed using reverse hybridization and immunohistochemistry for the presence of HPV and RAD51. Its effect on overall survival was examined. Results: Only two types of HPV were identified-HPV 16 (dominant) and HPV 66 (two samples). The HPV positivity was associated with a borderline insignificant improvement in 2-year (p = 0.083), 5-year (p = 0.159), and overall survival (p = 0.083). Similarly, the RAD51 overexpression was associated with borderline insignificant improvement in 2-year (p = 0.083) and 5-year (p = 0.159) survival. Conclusion: We found no statistically significant differences but detected trends toward improvement in the survival of HPV-positive and RAD51 overexpressing patients unfit for surgical treatment or chemotherapy treated with hyperfractionated radiotherapy. The trends, however, indicate that in a larger group of patients, the effects of these two parameters would likely be statistically significant.